Taiwan consensus statement on the management of chronic hepatitis B
The experts of Taiwan Association for the Study of Liver (TASL) have actively participated and led the guidelines on hepatitis B virus (HBV) management by Asian Pacific Association for the Study of Liver (APASL) which is the first international association for the study of liver to publish the state...
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2019-01-01
|
| Series: | Journal of the Formosan Medical Association |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S092966461830737X |
| _version_ | 1811266677190426624 |
|---|---|
| author | Rong-Nan Chien Jia-Horng Kao Cheng-Yuan Peng Chien-Hung Chen Chun-Jen Liu Yi-Hsiang Huang Tsung-Hui Hu Hwa-I Yang Sheng-Nan Lu Yen-Hsuan Ni Won-Long Chuang Chuan-Mo Lee Jaw-Chin Wu Pei-Jer Chen Yun-Fan Liaw |
| author_facet | Rong-Nan Chien Jia-Horng Kao Cheng-Yuan Peng Chien-Hung Chen Chun-Jen Liu Yi-Hsiang Huang Tsung-Hui Hu Hwa-I Yang Sheng-Nan Lu Yen-Hsuan Ni Won-Long Chuang Chuan-Mo Lee Jaw-Chin Wu Pei-Jer Chen Yun-Fan Liaw |
| author_sort | Rong-Nan Chien |
| collection | DOAJ |
| description | The experts of Taiwan Association for the Study of Liver (TASL) have actively participated and led the guidelines on hepatitis B virus (HBV) management by Asian Pacific Association for the Study of Liver (APASL) which is the first international association for the study of liver to publish the statement on HBV management before. However, there are more and more new data on the natural history and treatment of HBV infection in the past decade. These include new application of an old biomarker (quantitative HBsAg), clinical significance of HBV genotype and naturally occurring mutations, the role of non-invasive examination in evaluating severity of hepatic fibrosis, clinical significance of outcome calculators, new drug or new combination strategies towards more effective therapy and organ transplantation including liver and non-liver transplantation. It is time to publish the guidelines on HBV management of Taiwan. Hence, TASL have conducted an expert meeting to review, to discuss and to debate the relevant literatures, followed by draft the manuscript of HBV management guidelines and recommendations. The guidelines include general management, indications for fibrosis assessment, time to start or stop drug therapy, choice of drug to initiate therapy, when and how to monitor the patients during and after stopping drug therapy. Recommendations on the therapy of patients in special circumstances, including women in childbearing age, patients with antiviral drug resistance, concurrent viral infection, hepatic decompensation, patient receiving immune suppression or chemotherapy and patients in the setting of liver transplantation and hepatocellular carcinoma, are also included. Keywords: Chronic hepatitis B, Pegylated interferon alfa, Entecavir, Tenofovir disoproxil fumarate, Tenofovir alafenamide |
| first_indexed | 2024-04-12T20:47:35Z |
| format | Article |
| id | doaj.art-e7ef9c0045174d1485ab6ba12ce1195d |
| institution | Directory Open Access Journal |
| issn | 0929-6646 |
| language | English |
| last_indexed | 2024-04-12T20:47:35Z |
| publishDate | 2019-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Journal of the Formosan Medical Association |
| spelling | doaj.art-e7ef9c0045174d1485ab6ba12ce1195d2022-12-22T03:17:14ZengElsevierJournal of the Formosan Medical Association0929-66462019-01-011181738Taiwan consensus statement on the management of chronic hepatitis BRong-Nan Chien0Jia-Horng Kao1Cheng-Yuan Peng2Chien-Hung Chen3Chun-Jen Liu4Yi-Hsiang Huang5Tsung-Hui Hu6Hwa-I Yang7Sheng-Nan Lu8Yen-Hsuan Ni9Won-Long Chuang10Chuan-Mo Lee11Jaw-Chin Wu12Pei-Jer Chen13Yun-Fan Liaw14Liver Research Unit, Linkou Chang Gung Memorial Hospital and University College of Medicine, Taoyuan, Taiwan; Corresponding author. Liver Research Unit, Linkou Chang Gung Memorial Hospital and University College of Medicine, No. 5, Fuxing Street, Guishan Dist., Taoyuan, 333, Taiwan. Fax: +886 3 3272236.Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine and Hospital, Taipei, TaiwanDivision of Hepatogastroenterology, Department of Internal Medicine, China Medical University Hospital, Taichung, TaiwanDivision of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, TaiwanGraduate Institute of Clinical Medicine, Department of Internal Medicine and Hepatitis Research Center, National Taiwan University College of Medicine and Hospital, Taipei, TaiwanDivision of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Clinical Medicine, National Yang-Ming University School of Medicine, Taipei, TaiwanDivision of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, TaiwanDepartment of Genomic Research Center, Sinica Academia, Taipei, TaiwanDivision of Hepatogastroenterology, Department of Internal Medicine, Chiayi Chang Gung Memorial Hospital, Chiayi, TaiwanDepartment of Pediatrics, National Taiwan University College of Medicine and Children's Hospital, Taipei, TaiwanDivision of Hepatobiliary and Pancreas, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, TaiwanDivision of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, TaiwanDivision of Gastroenterology and Hepatology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Clinical Medicine, National Yang-Ming University School of Medicine, Taipei, TaiwanGraduate Institute of Clinical Medicine, National Taiwan University College of Medicine and Hospital, Taipei, TaiwanLiver Research Unit, Linkou Chang Gung Memorial Hospital and University College of Medicine, Taoyuan, TaiwanThe experts of Taiwan Association for the Study of Liver (TASL) have actively participated and led the guidelines on hepatitis B virus (HBV) management by Asian Pacific Association for the Study of Liver (APASL) which is the first international association for the study of liver to publish the statement on HBV management before. However, there are more and more new data on the natural history and treatment of HBV infection in the past decade. These include new application of an old biomarker (quantitative HBsAg), clinical significance of HBV genotype and naturally occurring mutations, the role of non-invasive examination in evaluating severity of hepatic fibrosis, clinical significance of outcome calculators, new drug or new combination strategies towards more effective therapy and organ transplantation including liver and non-liver transplantation. It is time to publish the guidelines on HBV management of Taiwan. Hence, TASL have conducted an expert meeting to review, to discuss and to debate the relevant literatures, followed by draft the manuscript of HBV management guidelines and recommendations. The guidelines include general management, indications for fibrosis assessment, time to start or stop drug therapy, choice of drug to initiate therapy, when and how to monitor the patients during and after stopping drug therapy. Recommendations on the therapy of patients in special circumstances, including women in childbearing age, patients with antiviral drug resistance, concurrent viral infection, hepatic decompensation, patient receiving immune suppression or chemotherapy and patients in the setting of liver transplantation and hepatocellular carcinoma, are also included. Keywords: Chronic hepatitis B, Pegylated interferon alfa, Entecavir, Tenofovir disoproxil fumarate, Tenofovir alafenamidehttp://www.sciencedirect.com/science/article/pii/S092966461830737X |
| spellingShingle | Rong-Nan Chien Jia-Horng Kao Cheng-Yuan Peng Chien-Hung Chen Chun-Jen Liu Yi-Hsiang Huang Tsung-Hui Hu Hwa-I Yang Sheng-Nan Lu Yen-Hsuan Ni Won-Long Chuang Chuan-Mo Lee Jaw-Chin Wu Pei-Jer Chen Yun-Fan Liaw Taiwan consensus statement on the management of chronic hepatitis B Journal of the Formosan Medical Association |
| title | Taiwan consensus statement on the management of chronic hepatitis B |
| title_full | Taiwan consensus statement on the management of chronic hepatitis B |
| title_fullStr | Taiwan consensus statement on the management of chronic hepatitis B |
| title_full_unstemmed | Taiwan consensus statement on the management of chronic hepatitis B |
| title_short | Taiwan consensus statement on the management of chronic hepatitis B |
| title_sort | taiwan consensus statement on the management of chronic hepatitis b |
| url | http://www.sciencedirect.com/science/article/pii/S092966461830737X |
| work_keys_str_mv | AT rongnanchien taiwanconsensusstatementonthemanagementofchronichepatitisb AT jiahorngkao taiwanconsensusstatementonthemanagementofchronichepatitisb AT chengyuanpeng taiwanconsensusstatementonthemanagementofchronichepatitisb AT chienhungchen taiwanconsensusstatementonthemanagementofchronichepatitisb AT chunjenliu taiwanconsensusstatementonthemanagementofchronichepatitisb AT yihsianghuang taiwanconsensusstatementonthemanagementofchronichepatitisb AT tsunghuihu taiwanconsensusstatementonthemanagementofchronichepatitisb AT hwaiyang taiwanconsensusstatementonthemanagementofchronichepatitisb AT shengnanlu taiwanconsensusstatementonthemanagementofchronichepatitisb AT yenhsuanni taiwanconsensusstatementonthemanagementofchronichepatitisb AT wonlongchuang taiwanconsensusstatementonthemanagementofchronichepatitisb AT chuanmolee taiwanconsensusstatementonthemanagementofchronichepatitisb AT jawchinwu taiwanconsensusstatementonthemanagementofchronichepatitisb AT peijerchen taiwanconsensusstatementonthemanagementofchronichepatitisb AT yunfanliaw taiwanconsensusstatementonthemanagementofchronichepatitisb |